Intermediate dry age-related macular degeneration

Allegro successfully completed a Phase 2a trial of patients with intermediate dry AMD, the results of which were presented at different national and international congresses in 2019 and 2020. Allegro is preparing to initiate a Phase 2b/3 clinical program. Read more about completed Phase 2a studies on

Dry eye disease

ALG-1007 demonstrated promising results in an ex-U.S. proof-of-concept clinical trial, in which it showed efficacy, a significant dose response curve, and that it was well-tolerated with no adverse events. A second and larger ex-U.S. Phase 2 clinical trial was successfully completed.